UK Set To Launch Drug Repurposing Project
Plans Include Extended Protection Periods And New ‘Catalyst Fund’
Executive Summary
Licensing new uses of existing medicines has several benefits over off-label use, such as offering assurances that the indication is evidence based and subject to an ongoing safety monitoring program, according to a new report.
You may also be interested in...
UK Weathers Challenges Of COVID-19 And Brexit
Departing BGMA leader Warwick Smith highlights successes in the UK off-patent industry’s response to the COVID-19 pandemic but offers unambiguous criticism of Brexit in the concluding part of an exclusive interview with Generics Bulletin.
EU Drug Repurposing Project To Kick Off In Q1 2020
Finding new uses for older drugs is the objective of a European repurposing project that will begin in early 2020.
Coronavirus Notebook: WHO’s Plan For Vaccine Manufacturing In Lower-Income Countries, UK Urged To Back IP Waiver
The UK’s independent vaccines committee has finalized its recommendations for the second phase of the COVID-19 vaccination program, and safety issues with several vaccines are still hitting the headlines.